Literature DB >> 26306634

Structural determinants of heparin-transforming growth factor-β1 interactions and their effects on signaling.

Jonathan Lee1, Sheena Wee2, Jayantha Gunaratne2, R J E Chua3, Raymond A A Smith3, Ling Ling3, David G Fernig4, Kunchithapadam Swaminathan5, Victor Nurcombe6, Simon M Cool7.   

Abstract

Transforming growth factor-β1 (TGF-β1, Uniprot: P01137) is a heparin-binding protein that has been implicated in a number of physiological processes, including the initiation of chondrogenesis by human mesenchymal stem cells (hMSCs). Here, we identify the molecular features in the protein and in heparin required for binding and their effects on the potentiation of TGF-β1's activity on hMSCs. Using a proteomics "Protect and Label" approach, lysines K291, K304, K309, K315, K338, K373, K375 and K388 were identified as being directly involved in binding heparin (Data are available via ProteomeXchange with identifier PXD002772). Competition assays in an optical biosensor demonstrated that TGF-β1 does require N- and 6-O-sulfate groups for binding but that 2-O-sulfate groups are unlikely to underpin the interaction. Heparin-derived oligosaccharides as short as degree of polymerization (dp) 4 have a weak ability to compete for TGF-β1 binding to heparin, which increases with the length of the oligosaccharide to reach a maximum between dp18 and dp24. In cell-based assays, heparin, 2-O-, 6-O- and N-desulfated re-N-acetylated heparin and oligosaccharides 14-24 saccharides (dp14-24) in length all increased the phosphorylation of mothers against decapentaplegic homolog 2 (SMAD2) after 6 h of stimulation with TGF-β1. The results provide the structural basis for a model of heparin/heparan sulfate binding to TGF-β1 and demonstrate that the features in the polysaccharide required for binding are not identical to those required for sustaining the signaling by TGF-β1 in hMSCs.
© The Author 2015. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  heparan sulfate; heparin; proteoglycans; transforming growth factor-β1

Mesh:

Substances:

Year:  2015        PMID: 26306634     DOI: 10.1093/glycob/cwv064

Source DB:  PubMed          Journal:  Glycobiology        ISSN: 0959-6658            Impact factor:   4.313


  13 in total

1.  Identification of the growth factor-binding sequence in the extracellular matrix protein MAGP-1.

Authors:  Thomas J Broekelmann; Nicholas K Bodmer; Robert P Mecham
Journal:  J Biol Chem       Date:  2020-01-27       Impact factor: 5.157

2.  A polyelectrolyte multilayer platform for investigating growth factor delivery modes in human liver cultures.

Authors:  Christine Lin; Raimundo Romero; Lioudmila V Sorokina; Kimberly R Ballinger; Laura W Place; Matt J Kipper; Salman R Khetani
Journal:  J Biomed Mater Res A       Date:  2017-12-04       Impact factor: 4.396

Review 3.  Proteoglycans and glycosaminoglycans in central nervous system injury.

Authors:  Noah Siddiqui; Kaori Oshima; Joseph A Hippensteel
Journal:  Am J Physiol Cell Physiol       Date:  2022-05-25       Impact factor: 5.282

4.  Cell number and chondrogenesis in human mesenchymal stem cell aggregates is affected by the sulfation level of heparin used as a cell coating.

Authors:  Jennifer Lei; Elda Trevino; Johnna Temenoff
Journal:  J Biomed Mater Res A       Date:  2016-03-28       Impact factor: 4.396

Review 5.  Extracellular matrix and traumatic brain injury.

Authors:  Naijil George; Herbert M Geller
Journal:  J Neurosci Res       Date:  2018-01-18       Impact factor: 4.164

6.  Sulfated Hyaluronan Derivatives Modulate TGF-β1:Receptor Complex Formation: Possible Consequences for TGF-β1 Signaling.

Authors:  Linda Koehler; Sergey Samsonov; Sandra Rother; Sarah Vogel; Sebastian Köhling; Stephanie Moeller; Matthias Schnabelrauch; Jörg Rademann; Ute Hempel; M Teresa Pisabarro; Dieter Scharnweber; Vera Hintze
Journal:  Sci Rep       Date:  2017-04-26       Impact factor: 4.379

Review 7.  The Good the Bad and the Ugly of Glycosaminoglycans in Tissue Engineering Applications.

Authors:  Bethanie I Ayerst; Catherine L R Merry; Anthony J Day
Journal:  Pharmaceuticals (Basel)       Date:  2017-06-13

8.  Growth Differentiation Factor 5-Mediated Enhancement of Chondrocyte Phenotype Is Inhibited by Heparin: Implications for the Use of Heparin in the Clinic and in Tissue Engineering Applications.

Authors:  Bethanie I Ayerst; Raymond A A Smith; Victor Nurcombe; Anthony J Day; Catherine L R Merry; Simon M Cool
Journal:  Tissue Eng Part A       Date:  2017-01-06       Impact factor: 3.845

9.  Supramolecular Platform Stabilizing Growth Factors.

Authors:  Simone I S Hendrikse; Sergio Spaans; E W Meijer; Patricia Y W Dankers
Journal:  Biomacromolecules       Date:  2018-05-02       Impact factor: 6.988

10.  Comparison of the Interactions of Different Growth Factors and Glycosaminoglycans.

Authors:  Fuming Zhang; Lanhong Zheng; Shuihong Cheng; Yanfei Peng; Li Fu; Xing Zhang; Robert J Linhardt
Journal:  Molecules       Date:  2019-09-16       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.